Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial

Kavanaugh A., COATES LC., Mease PJ., Nowak M., Hippeli L., Lehman T., Banerjee S., Merola JF.

Type

Journal

Rheumatology

Publisher

Oxford University Press (OUP)

Publication Date

15/10/2024

Permalink